. 2019 Dec;40(12):996–1002. [Article in Chinese] doi: 10.3760/cma.j.issn.0253-2727.2019.12.005
2019年版权归中华医学会所有
Copyright © 2019 by Chinese Medical Association
This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
图1. 不同Sokal危险度组服用尼洛替尼与伊马替尼患者的完全细胞遗传学反应（CCyR）获得率比较.
A：低危组；B：中危组；C：高危组